WHO Enhances Public Health Intelligence System to Strengthen Global Health Security
WHO Launches EIOS 2.0 to Strengthen Global Health Intelligence and Threat Detection The World Health Organization (WHO) today announced the official launch of version 2.0 of its Epidemic Intelligence from…
AbbVie to Share New Solid Tumor Therapy Data at ESMO 2025
AbbVie to Present Comprehensive Data on Antibody-Drug Conjugate Portfolio at ESMO 2025, Reinforcing Leadership in Targeted Solid Tumor Therapies AbbVie (NYSE: ABBV) announced today that it will present a robust…
FDA Updates RINVOQ® (upadacitinib) Label for Inflammatory Bowel Disease
AbbVie Announces FDA Approval of Updated RINVOQ® (upadacitinib) Indication for Inflammatory Bowel Disease NORTH CHICAGO, Ill., Oct. 13, 2025 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food…
LEQEMBI® IQLIK™ Autoinjector Named One of TIME’s Best Inventions of 2025
LEQEMBI® IQLIK™ Named One of TIME’s Best Inventions of 2025 for Transforming Alzheimer’s Treatment Access Eisai Co., Ltd. and Biogen Inc. today announced that LEQEMBI® IQLIK™ (lecanemab-irmb), the first subcutaneous…
Final Fintepla® OLE Study Results in Lennox-Gastaut Syndrome Published in Epilepsy & Behavior
UCB Publishes Final Analysis of Fintepla® Open-Label Extension Study in Lennox-Gastaut Syndrome Demonstrating Sustained Seizure Reduction and Improved Quality of Life UCB, a global biopharmaceutical company, announced that the final…
WuXi Biologics Applauds Sonoma Biotherapeutics Co-Founder and SAB Chair Dr. Fred Ramsdell on Winning the 2025 Nobel Prize in Physiology or Medicine
WuXi Biologics Applauds Sonoma Biotherapeutics Co-Founder Dr. Fred Ramsdell on Receiving the 2025 Nobel Prize in Physiology or Medicine WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing…
Neurology Study Shows 95% Reduction in Mortality with Pyrimidine Nucleos(t)ide Therapy in Patients with TK2 Deficiency
Neurology Publication Demonstrates 95% Reduction in Mortality Risk with Pyrimidine Nucleos(t)ide Therapy in Patients with Thymidine Kinase 2 Deficiency (TK2d) UCB, a global biopharmaceutical company focused on the discovery and…
Sonrotoclax Receives Breakthrough Therapy Designation from U.S. FDA
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA, Set to Participate in Project Orbis BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology-focused biopharmaceutical company,…
TIME Names LEQEMBI® IQLIK™ Subcutaneous Autoinjector Among 2025’s Best Inventions
LEQEMBI® IQLIK™ Subcutaneous Autoinjector Named One of TIME’s “Best Inventions of 2025” Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher…
GSK’s Shingrix Receives Approval in China to Prevent Shingles in Immunocompromised Adults Aged 18 and Older
GSK’s Shingrix Receives Approval in China to Protect Immunocompromised Adults Against Shingles GSK plc (LSE/NYSE: GSK) today announced that the China National Medical Products Administration (NMPA) has granted approval for…
DB-OTO Study Published in New England Journal of Medicine Demonstrates Significant, Lasting Gains in Hearing and Speech for Children with Profound Genetic Hearing Loss
Regeneron Presents Latest DB-OTO Data Showing Dramatic and Sustained Hearing and Speech Improvements in Children with Profound Genetic Hearing Loss Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for…
CVS Health® 2025 Rx Report Reveals How Community Pharmacies Are Evolving to Better Serve Patients
CVS Health® 2025 Rx Report Highlights the Evolution of Community Pharmacy to Meet Patient Needs CVS Health® (NYSE: CVS) today unveiled its 2025 Rx Report, Community Pharmacy Reimagined, offering a…